Skip Nav Destination
Issues
1 April 2015
-
Cover Image
Cover Image
The image shows the 4 stable subtypes of triple-negative breast cancer defined by gene signature. These subtypes (luminal androgen receptor, mesenchymal, basal-like immunosuppressed, and basal-like immune-activated) are characterized by the expression of distinct molecular profiles that have disparate prognoses. For details, see the article by Burstein and colleagues on page 1688 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Issue Sections
Highlights
20th Anniversary Commentary
CCR Translations
CCR Perspectives in Drug Approval
Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400
Roy S. Herbst; David R. Gandara; Fred R. Hirsch; Mary W. Redman; Michael LeBlanc; Philip C. Mack; Lawrence H. Schwartz; Everett Vokes; Suresh S. Ramalingam; Jeffrey D. Bradley; Dana Sparks; Yang Zhou; Crystal Miwa; Vincent A. Miller; Roman Yelensky; Yali Li; Jeff D. Allen; Ellen V. Sigal; David Wholley; Caroline C. Sigman; Gideon M. Blumenthal; Shakun Malik; Gary J. Kelloff; Jeffrey S. Abrams; Charles D. Blanke; Vassiliki A. Papadimitrakopoulou
FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma
Barry W. Miller; Donna Przepiorka; R. Angelo de Claro; Kyung Lee; Lei Nie; Natalie Simpson; Ramadevi Gudi; Haleh Saber; Stacy Shord; Julie Bullock; Dhananjay Marathe; Nitin Mehrotra; Li Shan Hsieh; Debasis Ghosh; Janice Brown; Robert C. Kane; Robert Justice; Edvardas Kaminskas; Ann T. Farrell; Richard Pazdur
Statistics in Clinical Cancer Research
CCR Drug Updates
Molecular Pathways
Review
Cancer Therapy: Clinical
A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report
Maryam Fouladi; John P. Perentesis; Lars M. Wagner; Alexander A. Vinks; Joel M. Reid; Charlotte Ahern; George Thomas; Carol A. Mercer; Darcy A. Krueger; Peter J. Houghton; L. Austin Doyle; Helen Chen; Brenda Weigel; Susan M. Blaney
A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma
Thomas J. Galloway; Lori J. Wirth; Alexander D. Colevas; Jill Gilbert; Julie E. Bauman; Nabil F. Saba; David Raben; Ranee Mehra; Anna W. Ma; Ruzanna Atoyan; Jing Wang; Barbara Burtness; Antonio Jimeno
Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer
Shivaani Kummar; Amit M. Oza; Gini F. Fleming; Daniel M. Sullivan; David R. Gandara; Michael J. Naughton; Miguel A. Villalona-Calero; Robert J. Morgan, Jr; Peter M. Szabo; Ahrim Youn; Alice P. Chen; Jiuping Ji; Deborah E. Allen; Chih-Jian Lih; Michele G. Mehaffey; William D. Walsh; Paul M. McGregor, III; Seth M. Steinberg; P. Mickey Williams; Robert J. Kinders; Barbara A. Conley; Richard M. Simon; James H. Doroshow
Personalized Medicine and Imaging
Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation
Pierre Bohanes; Cathryn J. Rankin; Charles D. Blanke; Thomas Winder; Cornelia M. Ulrich; Stephen R. Smalley; Tyvin A. Rich; James A. Martensen; Al B. Benson, III; Robert J. Mayer; Christine M. Cripps; Kathleen Danenberg; Karen W. Makar; Wu Zhang; Jacqueline K. Benedetti; Heinz-Josef Lenz
Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate
Gerhardt Attard; Johann S. de Bono; Christopher J. Logothetis; Karim Fizazi; Som D. Mukherjee; Anthony M. Joshua; Dirk Schrijvers; Alfons J.M. van den Eertwegh; Weimin Li; Arturo Molina; Thomas W. Griffin; Thian Kheoh; Deborah S. Ricci; Kathy Zelinsky; Dana E. Rathkopf; Howard I. Scher; Charles J. Ryan
Cancer Therapy: Preclinical
The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
Michela Boi; Eugenio Gaudio; Paola Bonetti; Ivo Kwee; Elena Bernasconi; Chiara Tarantelli; Andrea Rinaldi; Monica Testoni; Luciano Cascione; Maurilio Ponzoni; Afua Adjeiwaa Mensah; Anastasios Stathis; Georg Stussi; María Eugenia Riveiro; Patrice Herait; Giorgio Inghirami; Esteban Cvitkovic; Emanuele Zucca; Francesco Bertoni
The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
Li Liu; Patrick A. Mayes; Stephen Eastman; Hong Shi; Sapna Yadavilli; Tianqian Zhang; Jingsong Yang; Laura Seestaller-Wehr; Shu-Yun Zhang; Chris Hopson; Lyuben Tsvetkov; Junping Jing; Shu Zhang; James Smothers; Axel Hoos
BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth
Tao Wang; Min Xiao; Yingbin Ge; Clemens Krepler; Eric Belser; Alfonso Lopez-Coral; Xiaowei Xu; Gao Zhang; Rikka Azuma; Qin Liu; Rui Liu; Ling Li; Ravi K. Amaravadi; Wei Xu; Giorgos Karakousis; Tara C. Gangadhar; Lynn M. Schuchter; Melissa Lieu; Sanika Khare; Molly B. Halloran; Meenhard Herlyn; Russel E. Kaufman
A Novel CDC25B Promoter–Based Oncolytic Adenovirus Inhibited Growth of Orthotopic Human Pancreatic Tumors in Different Preclinical Models
Helga L. Weber; Manuel Gidekel; Santiago Werbajh; Edgardo Salvatierra; Cecilia Rotondaro; Leonardo Sganga; Gabriela Acosta Haab; David T. Curiel; Eduardo G. Cafferata; Osvaldo L. Podhajcer
Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth
Yoshiaki Yamamoto; Yohann Loriot; Eliana Beraldi; Fan Zhang; Alexander W. Wyatt; Nader Al Nakouzi; Fan Mo; Tianyuan Zhou; Youngsoo Kim; Brett P. Monia; A. Robert MacLeod; Ladan Fazli; Yuzhuo Wang; Colin C. Collins; Amina Zoubeidi; Martin Gleave
Biology of Human Tumors
Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
Matthew D. Burstein; Anna Tsimelzon; Graham M. Poage; Kyle R. Covington; Alejandro Contreras; Suzanne A.W. Fuqua; Michelle I Savage; C. Kent Osborne; Susan G. Hilsenbeck; Jenny C. Chang; Gordon B. Mills; Ching C. Lau; Powel H. Brown
Loss of SOD3 (EcSOD) Expression Promotes an Aggressive Phenotype in Human Pancreatic Ductal Adenocarcinoma
Brianne R. O'Leary; Melissa A. Fath; Andrew M. Bellizzi; Jennifer E. Hrabe; Anna M. Button; Bryan G. Allen; Adam J. Case; Sean Altekruse; Brett A. Wagner; Garry R. Buettner; Charles F. Lynch; Brenda Y. Hernandez; Wendy Cozen; Robert A. Beardsley; Jeffery Keene; Michael D. Henry; Frederick E. Domann; Douglas R. Spitz; James J. Mezhir
BATF2 Deficiency Promotes Progression in Human Colorectal Cancer via Activation of HGF/MET Signaling: A Potential Rationale for Combining MET Inhibitors with IFNs
Zebing Liu; Ping Wei; Yu Yang; Wenli Cui; Bing Cao; Cong Tan; Baohua Yu; Rui Bi; Kaiqin Xia; Weixiang Chen; Yiqin Wang; Youyuan Zhang; Xiang Du; Xiaoyan Zhou
Corrections
Advertisement
